Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to $213000.0.

  • Perspective Therapeutics' Cash from Financing Activities fell 6608.28% to $213000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year decrease of 9631.54%. This contributed to the annual value of $289.4 million for FY2024, which is 3676433.12% up from last year.
  • Latest data reveals that Perspective Therapeutics reported Cash from Financing Activities of $213000.0 as of Q3 2025, which was down 6608.28% from $132000.0 recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' Cash from Financing Activities registered a high of $166.3 million during Q1 2024, and its lowest value of -$80000.0 during Q1 2023.
  • In the last 5 years, Perspective Therapeutics' Cash from Financing Activities had a median value of $345000.0 in 2024 and averaged $23.8 million.
  • Per our database at Business Quant, Perspective Therapeutics' Cash from Financing Activities skyrocketed by 20801000.0% in 2024 and then plummeted by 9989.19% in 2025.
  • Over the past 5 years, Perspective Therapeutics' Cash from Financing Activities (Quarter) stood at $28000.0 in 2021, then changed by 0.0% to $28000.0 in 2022, then soared by 1157.14% to $352000.0 in 2023, then fell by 1.99% to $345000.0 in 2024, then crashed by 38.26% to $213000.0 in 2025.
  • Its Cash from Financing Activities stands at $213000.0 for Q3 2025, versus $132000.0 for Q2 2025 and $10.0 million for Q1 2025.